{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:39:55Z","timestamp":1790015995972,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100015511","name":"Savara Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015511","name":"Savara Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015511","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Inhaled granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) has been proposed as a potential immunomodulatory treatment for nontuberculous mycobacterial (NTM) infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This open-label, noncomparative pilot trial investigated the efficacy and safety of inhaled GM-CSF (molgramostim nebulizer solution) in patients with predominantly treatment-refractory pulmonary NTM infection (Mycobacterium avium complex [MAC] and M. abscessus [MABS]), either in combination with ongoing guideline-based therapy (GBT) or as monotherapy in patients who had stopped GBT because of lack of efficacy or intolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-two adult patients with refractory NTM infection (MAC, n\u2009=\u200924; MABS, n\u2009=\u20098) were recruited into two cohorts: those with (n\u2009=\u200916) and without (n\u2009=\u200916) ongoing GBT. Nebulized molgramostim 300 \u03bcg\/d was administered over 48\u2009weeks. Sputum cultures and smears and clinical assessments (6-min-walk distance, symptom scores, Quality of Life\u2013Bronchiectasis Questionnaire score, and body weight) were collected every 4\u2009weeks during treatment and 12\u2009weeks after the end of treatment. The primary endpoint was sputum culture conversion, defined as three consecutive monthly negative cultures during the treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight patients (25%) achieved culture conversion on treatment (seven [29.2%] patients with MAC infection, one [12.5%] patient with MABS infection); in four patients, this was durable after the end of treatment. Of the 24 patients with MAC infection, an additional 4 patients had a partial response, converting from smear positive at baseline to smear negative at the end of treatment, and time to positivity in liquid culture media increased. Two of these patients sustained negative cultures from the end of treatment. Other clinical endpoints were unchanged. Serious adverse events were mainly pulmonary exacerbations or worsening NTM infection. Three deaths, not treatment related, were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this population of patients with severe NTM disease, molgramostim was safe and well tolerated. Sputum culture conversion rates for patients with MAC infection (29.2%) were greater than reported for similar refractory MAC cohorts managed with GBT alone. Less benefit was seen for MABS infection. No serious safety concerns were identified. Further evaluation in a larger cohort is warranted.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT03421743).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202306-532oc","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T16:56:05Z","timestamp":1699635365000},"page":"568-576","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":20,"title":["OPTIMA: An Open-Label, Noncomparative Pilot Trial of Inhaled Molgramostim in Pulmonary Nontuberculous Mycobacterial Infection"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-171X","authenticated-orcid":false,"given":"Rachel M.","family":"Thomson","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, University of Queensland, Brisbane, Queensland, Australia"},{"name":"Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia"},{"name":"The Prince Charles Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Burke","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of Queensland, Brisbane, Queensland, Australia"},{"name":"The Prince Charles Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Concord Repatriation Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant W.","family":"Waterer","sequence":"additional","affiliation":[{"name":"East Metropolitan Health Service, Royal Perth Bentley Group, University of Western Australia, Perth, Western Australia, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Ganslandt","sequence":"additional","affiliation":[{"name":"Savara Inc., Hoersholm, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"2026012203145847400_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of nontuberculous mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"key":"2026012203145847400_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026012203145847400_bib3","doi-asserted-by":"crossref","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"2026012203145847400_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"2026012203145847400_bib5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"2026012203145847400_bib6","author":"Savara Pharmaceuticals","year":"2019"},{"key":"2026012203145847400_bib7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00018-016-2422-8","article-title":"Molecular basis of mycobacterial survival in macrophages","volume":"74","author":"Awuh","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"2026012203145847400_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2016.03.006","article-title":"Update on pulmonary disease due to non-tuberculous mycobacteria","volume":"45","author":"Stout","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2026012203145847400_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12038-008-0029-4","article-title":"Mycobacteria and innate cells: critical encounter for immunogenicity","volume":"33","author":"Martino","year":"2008","journal-title":"J Biosci"},{"key":"2026012203145847400_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1615\/CritRevImmunol.v25.i5.50","article-title":"Functions of granulocyte-macrophage colony-stimulating factor","volume":"25","author":"Fleetwood","year":"2005","journal-title":"Crit Rev Immunol"},{"key":"2026012203145847400_bib11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/ajrccm\/146.5_Pt_1.1279","article-title":"The effect of aerosolized recombinant human granulocyte macrophage colony-stimulating factor on lung leukocytes in nonhuman primates","volume":"146","author":"Rose","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2026012203145847400_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/infdis\/169.3.575","article-title":"Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model","volume":"169","author":"Bermudez","year":"1994","journal-title":"J Infect Dis"},{"key":"2026012203145847400_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jlb.48.1.67","article-title":"Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex","volume":"48","author":"Bermudez","year":"1990","journal-title":"J Leukoc Biol"},{"key":"2026012203145847400_bib14","first-page":"OA1603","article-title":"Use of inhaled GM-CSF in treatment refractory NTM infection: an open-label, exploratory clinical trial [abstract]","volume":"58","author":"Thomson","year":"2021","journal-title":"Eur Respir J"},{"key":"2026012203145847400_bib15","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1038\/s41598-023-33782-z","article-title":"Usefulness of the BACES score in nontuberculous mycobacterial pulmonary disease for various clinical outcomes","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"2026012203145847400_bib16","doi-asserted-by":"crossref","first-page":"e20210745","DOI":"10.1084\/jem.20210745","article-title":"Alveolar macrophages rely on GM-CSF from alveolar epithelial type 2 cells before and after birth","volume":"218","author":"Gschwend","year":"2021","journal-title":"J Exp Med"},{"key":"2026012203145847400_bib17","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1073\/pnas.91.12.5592","article-title":"Granulocyte\/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology","volume":"91","author":"Stanley","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012203145847400_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkt451","article-title":"GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus","volume":"69","author":"De Groote","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026012203145847400_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1172\/JCI5212","article-title":"GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection","volume":"103","author":"LeVine","year":"1999","journal-title":"J Clin Invest"},{"key":"2026012203145847400_bib20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1165\/rcmb.2005-0246OC","article-title":"Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa","volume":"34","author":"Ballinger","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012203145847400_bib21","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.4049\/jimmunol.1101413","article-title":"Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia","volume":"187","author":"Steinwede","year":"2011","journal-title":"J Immunol"},{"key":"2026012203145847400_bib22","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1172\/JCI62139","article-title":"Alveolar epithelial cells orchestrate DC function in murine viral pneumonia","volume":"122","author":"Unkel","year":"2012","journal-title":"J Clin Invest"},{"key":"2026012203145847400_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1164\/rccm.200812-1837OC","article-title":"Macrophage tumor necrosis factor-\u03b1 induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair","volume":"180","author":"Cakarova","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203145847400_bib24","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0002-9440(10)63594-8","article-title":"Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury","volume":"163","author":"Paine","year":"2003","journal-title":"Am J Pathol"},{"key":"2026012203145847400_bib25","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.jinf.2006.11.005","article-title":"The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection","volume":"54","author":"de Silva","year":"2007","journal-title":"J Infect"},{"key":"2026012203145847400_bib26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1086\/315191","article-title":"Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes\/macrophages in vitro and in vivo","volume":"181","author":"Kedzierska","year":"2000","journal-title":"J Infect Dis"},{"key":"2026012203145847400_bib27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1086\/515249","article-title":"Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor","volume":"177","author":"Kemper","year":"1998","journal-title":"J Infect Dis"},{"key":"2026012203145847400_bib28","doi-asserted-by":"crossref","first-page":"1702127","DOI":"10.1183\/13993003.02127-2017","article-title":"Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis","volume":"51","author":"Scott","year":"2018","journal-title":"Eur Respir J"},{"key":"2026012203145847400_bib29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1913590","article-title":"Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosis","volume":"383","author":"Trapnell","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012203145847400_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203145847400_bib31","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203145847400_bib32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"2026012203145847400_bib33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1513\/AnnalsATS.202107-765OC","article-title":"Time to positive culture detection predicts Mycobacterium avium pulmonary disease severity and treatment initiation","volume":"19","author":"Edwards","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203145847400_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.chest.2021.08.046","article-title":"Mycobacterium growth indicator tube time-to-positivity can serve as an early biomarker of treatment response in Mycobacterium avium complex pulmonary disease","volume":"161","author":"Danho","year":"2022","journal-title":"Chest"},{"key":"2026012203145847400_bib35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12879-022-07250-4","article-title":"Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion","volume":"22","author":"Mingora","year":"2022","journal-title":"BMC Infect Dis"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/4\/568\/66009646\/annalsats_21_4_568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/4\/568\/66009646\/annalsats_21_4_568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:16:00Z","timestamp":1769069760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/4\/568\/8382038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202306-532oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2023-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}